The value of detection of S100A8 and ASAH1 in predicting the chemotherapy response for breast cancer patients

Hum Pathol. 2018 Apr;74:156-163. doi: 10.1016/j.humpath.2018.01.004. Epub 2018 Jan 7.

Abstract

Chemotherapy plays an important role in the treatment of breast cancer. However, chemoresistance remains the main obstacle for effective treatment, leading to poor prognosis. This study aims to investigate the value of detection of S100A8 and ASAH1 in predicting the chemotherapy response. Miller and Payne grades were used to assess the chemotherapy response in breast cancers. The expression of S100A8 and ASAH1, as well as ER, PR, HER2 and Ki-67 were assessed by immunohistochemical staining in 120 cases of non-special type invasive ductal carcinoma (IDC-NOS). S100A8 expression was higher in chemosensitive breast cancers than chemoresistant ones. Moreover, S100A8 expression was significantly correlated with the molecular subtypes and histological grade, but not with patients' age, tumor size and lymph nodes status. However, there was no significant difference in ASAH1 expression between chemoresistant and chemosensitive group. We also found that higher ASAH1 expression was correlated with positive lymph nodes status, but not with age, tumor size, molecular subtypes and histological grade. S100A8 was valuable in predicting chemotherapy response in breast cancers. The expression of ASAH1 was associated significantly with lymph nodes metastasis, indicating that ASAH1 may serve as a biomarker to predict patients' lymph nodes status in breast cancers.

Keywords: ASAH1; Breast cancer; Drug resistance; Neoadjuvant chemotherapy; S100A8.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acid Ceramidase / metabolism*
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Calgranulin A / metabolism*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / metabolism
  • Carcinoma, Ductal, Breast / pathology
  • Female
  • Humans
  • Lymphatic Metastasis / pathology*
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / metabolism
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Calgranulin A
  • Receptor, ErbB-2
  • ASAH1 protein, human
  • Acid Ceramidase